Spinnovation launches biologics analysis division

Published: 8-Apr-2011
Finance Analysis Pharmaceutical

Spinnovation Biologics to provide profiling and characterisation of biologics

Spinnovation Analytical, a Dutch contract research organisation, has launched a new division called Spinnovation Biologics, which will provide spent culture media analysis and profiling and characterisation of biologics and biosimilar drugs.

Frederic Girard, chief executive of the Nijmegen-based nuclear magnetic resonance spectroscopy (NMR) specialist, said spent media analysis with Spedia-NMR would be the new company’s core service.

‘Spedia-NMR is unique and can deliver a step-fold increase in throughput and detail over standard methods, in as few as five working days,’ he said.

Spinnovation Biologics will also offer process and product bioanalysis, enabling clients to benefit from advanced insights into cell culture to enhance productivity, scalability, and reliability for QA/QC control, cGMP production and support Quality by Design.

In addition to Spedia-NMR technology, Spinnovation Biologics has a broad spectrum of analysis methods in house, including: LC-MS, LC-NMR, LC-SPE-NMR and LC-SPE-NMR-MS.

See more

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

Read more
To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands

Trending Articles

  1. Thermo Fisher Scientific doubles down on investment in Asia New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
  2. Gentle and rapid detachment of even delicate adherent cells Detachin™ Cell Detachment Solution from Amsbio provides a superior alternative to Trypsin/EDTA for gentle detachment of adherent cells from in vitro growth vessels
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Stop reviewing good data: review‑by‑exception for chromatography QC Labs spend hours confirming routine chromatograms while real risks hide in plain sight; regulators support a better path if data are captured and surfaced correctly, notes George Van Den Driessche, Data Science Product Manager at TetraScience
  4. AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
  5. EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands
Analysis

Spinnovation Biologics predicts bioproduction performance

With the launch of Spedia-Predict
Pharmaceutical

Spinnovation introduces approach to improve biologicals manufacturing processes

Spinnovation technology delivers optimal cell viability and density, with the right safety and quality parameters in a short time frame
Analysis

Spinnovation Biologics offers service choices to meet individual analysis needs for bioprocess optimisation

Unique mix of services delivers essential support for the development and manufacture of biologics
Pharmaceutical

Cytiva and Fida Biosystems unite to improve molecular insight for faster drug discovery

The collaboration will combine complementary and orthogonal approaches to simplify workflows and improve confidence in experimental results
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Subscribe now